Predictors and incidence of sexually transmitted Hepatitis C virus infection in HIV positive men who have sex with men

Table 2 Incidence, crude and adjusted hazards ratio for incidence HCV infection. Cox Regression Analysis

	Incident HCV cases	PYs	Incidence (cases/100PY)	Unadjusted HR (95%CI)	p-value	Adjusted HR (95%CI)	p-value
Total	37	3114	1.19 (0.99–1.38)
Age^a	37	3193		0.61 (0.45–0.83)	.002	0.67 (0.48–0.92)	.014
Country of birth
Australia/New Zealand	26	1927	1.35 (1.08–1.61)	1 (ref)
Other	9	1053	0.85 (0.57–1.14)	0.64 (0.30–1.37)	0.250
CD4 count ^b
Most recent CD4	37	3114		1.11 (1.00–1.23)	.054	1.00 (0.85–1.18)	.965
Lowest CD4 ^c	37	3114		1.20 (0.95–1.52)	.121	1.26 (1.01–1.58)	.044
Year of HCV Test	37	3114		1.12 (0.94–1.34)	.208
HIV viral load suppression ^d
No	6	188	3.19 (1.89–4.49)	1 (ref)	–
Yes	31	2926	1.06 (0.87–1.25)	0.33 (0.14–0.79)	.012	0.51 (0.20–1.27)	.146
Exposure peri-incident syphilis^e
No	25	2859	0.87 (0.70–1.05)	1 (ref)	-
Yes	12	254	4.72 (3.35–6.08)	5.73 (2.86–11.45)	<.001	4.96 (2.46–9.99)	<.001
Exposure peri-incident anorectal chlamydia^f
No	31	2676	1.16 (0.95–1.93)	1 (ref)
Yes	6	438	1.37 (0.81–1.93)	1.19 (0.49–2.84)	.703
Ever HBV infected^g
No	29	2142	1.35 (1.10–1.61)	1 (ref)	-
Yes	8	972	0.82 (0.53–1.11)	0.61 (0.28–1.33)	.214

Notes
^aAge at beginning of testing interval (HR for increments of 10 years)
^bMost recent CD4 cell count before beginning of testing interval (HR for increments of 100cells/uL)
^cLowest ever recorded CD4 cell count (HR for increments of 100cells/uL)
^dMost recent viral load before beginning of testing interval less than 200 copies/ml
^eAny testing interval overlapping with a period 180 days before the beginning and 180 days after the end of the syphilis testing interval in which incident syphilis was diagnosed
^fAny testing interval overlapping with a period 180 days before the beginning and 180 days after the end of the anorectal chlamydia testing interval in which incident anorectal chlamydia was diagnosed
^gAny testing interval in any patient ever with positive HBV core antibody

ISSN: 1471-2334